Introduction
============

The resistance of ESBL-producing *Enterobacteriaceae* has currently become one of the most important nosocomial resistance problems around the world and it has been found that there are much more community-acquired ones ([@B7]; [@B28]). *Escherichia coli* has been a universal commensal bacterium causing infections in humans and animals and often leads to urinary tract infections (UTI) and bacteremia for humans ([@B23]). ESBL-producing *Enterobacteriaceae* were firstly reported in the middle of 1980s in Germany, since then a steady increase of these strains have been reported worldwide ([@B7]).

Recently, researchers have paid much more attention to extended spectrum beta-lactamases (ESBLs). As well known, the production of β-lactamase is the most common mechanism of bacterial resistance to β-lactam antibiotics; with the introduction of extended-spectrum cephalosporins, ESBLs has spread across the world ([@B21]; [@B31]; [@B26]; [@B32]). ESBLs could inactivate oxyimino-β-lactams like third-generation cephalosporins and aztreonam, but not hydrolyze the carbapenems, which are highly susceptible to inhibition by clavulanic acid and tazobactam ([@B18]). ESBL-producing strains are not only highly resistant to β-lactam antibiotics but also resistant to aminoglycosides, quinolones, sulfonamides, and so on ([@B16]).

The epidemic situation, resistance and genotype distribution of ESBL-producing strains have varied with different countries, regions and even hospitals. ESBL strains have extended all over the world stage by stage, while detectable rates have shown significant difference in different hospitals or areas of the same country. Previous researches have indicated the detectable rate of ESBL-producing strains from 5 to 8% of *Escherichia coli* Isolates in Korea, Japan, Malaysia, and Singapore, from 12 to 24% in Thailand, Taiwan, Philippines, and Indonesia ([@B23]), from 62 to 100% in India ([@B20]). By contrast, the rate was almost up to 60% in China ([@B29]).

Much more genetic subtypes of ESBLs have been found since 1980s, which has exceeded 200 so far. The vast majority of ESBLs belong to three types, including TEM, SHV, and CTX-M types ([@B4]; [@B3]; [@B7]; [@B23]; [@B19]; [@B9]). Previous researches exploring TEM-type has mainly involved the predominant genotype (particularly, TEM-10, TEM-12, and TEM-26) in north America ([@B25]; [@B27]); 92% ESBL-positive *E. coli* Isolates expressed a CTX-M-type enzyme from 2001 to 2006 and CTX-M-1 being the predominant group in Sweden ([@B14]); the CTX-M-15 enzyme was the most prevalent enzyme in United Kingdom ([@B2]; [@B19]). In China, the CTX-M β-lactamases was the most prevalent ESBLs, mainly including CTX-M-3, --9, --14, and --15 ([@B30]; [@B33]; [@B17]). In short, there exists tremendous variability in antimicrobial resistance amongst pathogens in different regions or in different hospitals located the same regions.

Given few wide-ranging survey researches in Shandong province, China, we aimed to explore ESBLs epidemiology, resistance and resistant genotypes of 289 *E. coli* strains Isolated from three hospitals in that area. In addition, we have collected clinical data about the patients to carry on further research. The study helps us reveal their distributions and local constitutions in that area, thus providing guidance for clinical treatment, and then contributing to avoiding delay the conditions of patients and medical resources waste.

Materials and Methods
=====================

Bacterial Strains
-----------------

We have collected 289 clinical Isolates of *E. coli* from patients in three typical hospitals of Shandong province in, China, from July 2013 to August 2014. There exist no replicate strains Isolated from one patient in our samples. Additional information has been collected with each Isolate, including isolation date, origin of the specimen, demographic details. Our experiment has been approved by Medical Ethics Committee of Shandong University School of Medicine (Grant No. 201401048).

ESBL Identification and Antimicrobial Susceptibility Testing
------------------------------------------------------------

Initially, all Isolates were tested using the Kirby Bauer disk diffusion method according to the [@B11]. *E. coli* ATCC25922 was used as control strains. The tested antibiotics included: ampicillin, ampicillin/sulbactam, amoxicillin/clavulanate, ticarcillin, piperacillin, piperacillin/tazobactam, cephalothin, cefuroxime, cefoxitin, ceftriaxone, cefotaxime, ceftazidime, cefepime, meropenem, and aztreonam (Mast Diagnostics, Merseyside, UK). co-trimoxazole, gentamicin, nalidixic acid, ciprofloxacin, imipenem, meropenem, tetracycline, and nitrofurantoin (Oxoid Ltd., Basingstoke, UK). MIC values were extrapolated by the BIOMIC automated reading system and software package (Giles Scientific, New York, NY, USA).

The disk diffusion method was applied to assess ESBL production in all the Isolates with cefotaxime (30 ug) and ceftazidime (30 ug) alone and in combination with clavulanic acid (10 ug) as recommended by the Clinical and Laboratory Standards Institute (CLSI).

Nucleic Acid Extractions
------------------------

DNA had been extracted from the Isolates by using boiling methods. Each strain was suspended in 500 ul of distilled water at concentration of MacFarland 0.5 and boiled at 100°C for 10 min. Then spined it in a centrifuge and kept the supernatant fluid in the --20°C freezer.

Polymerase Chain Reaction Detection and Sequencing of ESBLs
-----------------------------------------------------------

To determine the genotype of ESBLs, we performed polymerase chain reaction (PCR) amplification with the TEM and CTX-M. ESBLs Isolates were amplified with primers ([@B13]): 5′-ATGAGTATTC AACATTTCCGTG-3 and 5′-TTACCAATGCTTAATCAGTGAG-3, which have been designed to amplify TEM gene (length, 840 bp). Cycling conditions were as following: initial denaturation at 95°C for 3 min; 35 cycles of 95°C for 1 min, 55°C for 1 min and 72°C for 1 min; and a final elongation at 72°C for 5 min. We applied CTX-M gene primers: C1 (5′-SCSATGTGCAGYACCAGTAA-3) and C2 (5′-CCGCRAT ATGRTTGGTGGTG-3) to detect CTX-M gene (length, 554 bp). Cycling conditions were as follows: initial denaturation at 94°C for 3 min; 35 cycles of 94°C for 30S, 55°C for 30s and 72°C for 45s; and a final elongation at 72°C for 5 min. PCR reactions for each strain were repeated at least three times.

Sequencing of TEM and CTX-M genes
---------------------------------

The PCR products were purified with a QIA quick PCR purification kit (Qiagen, Hilden, Germany) and sequenced on an ABI Prism 377 automated sequencer (Perkin-Elmer, Norwalk, CT, USA). The primers for sequencing were the amplification primer. All sequences were confirmed by two independent determinations and analyzed by Basic Local Alignment Search Tool.

Results
=======

Bacterial Strains
-----------------

In our samples, these strains were Isolated mainly from patients in urinary surgery ward 110 (38.1%) and ICU 63 (21.8%). The rest in turn were derived from Respiratory Medicine, 27 (9.3%), Neurosurgery 22 (7.6%), Thoracic Surgery and General Surgery 21 (7.3%), Oncology 11 (3.8%), Orthopedic Surgery 9 (3.1%), Cardiovascular Medicine 9 (3.1%), Gastroenterology 8 (2.8%), Endocrinology 7 (2.4%), Neurology 2 (0.7%). A total of 197 ESBL-producing Isolates were detected phenotypically using the CLSI criteria for ESBL screening and disk confirmation test, the detection rate being 68.2% (197/289) (See Table [1](#T1){ref-type="table"}). We found that much more ESBL-producing Isolates exited in urinary surgery ward and ICU and the detection rate were higher than the other wards. The cohort of 197 patients had a mean age of 53.8, which ranges from 20 to 88 (See Table [2](#T2){ref-type="table"}). Of all Isolates, 109 (55.3%) patients were over 60. According to statistical results by age, we concluded that we should further enhance elderly patients' management and treatment dynamics, completes the prevention and treatment work. The main sources of ESBL- producing *E-coil* were unire 96 (48.73%, of total ESBL-producing Isolates), wounds 27 (13.71%), sputa 26 (13.20%), genital secretion 16 (8.12%), hydrothorax and ascite 15 (7.61%), blood 12 (6.09%), bile 5 (2.54%) (See Table [3](#T3){ref-type="table"}).

###### 

**Distribution of strains in different wards**.

  Wards                                  Total   ESBLs   Detection rate
  -------------------------------------- ------- ------- ----------------
  Urology                                110     74      67.27%
  Intensive care unit                    64      54      84.38%
  Respiratory medicine                   27      17      62.96%
  Neurosurgery                           22      13      59.09%
  Thoracic surgery and general surgery   21      13      61.90%
  Oncology                               11      7       63.64%
  Cardiovascular medicine                9       3       33.33%
  Orthopedic surgery                     9       5       55.56%
  Endocrinology                          8       5       62.50%
  Gastroenterology                       6       4       66.67%
  Neurology                              2       1       50.00%
  Total                                  289     197     68.2%

###### 

**Frequency of ESBL Isolates by age**.

  Age                          
  -------- ---- ---- ---- ---- -----
  Male     15   24   43   14   96
  Female   21   28   40   12   101
  Total    36   52   83   26   197

###### 

**Distribution of *E. coli* Isolates by type of specimen**.

  Specimen type            Total   ESBLs   Non-ESBLs
  ------------------------ ------- ------- -----------
  Unire                    126     96      30
  Wounds                   42      27      15
  Sputa                    38      26      12
  Genital secretion        28      16      12
  Hydrothorax and ascite   26      15      11
  Blood                    20      12      8
  Bile                     9       5       4
  Total                    289     197     92

Antimicrobial Susceptibility
----------------------------

The ESBL-producing Isolates were often multidrug-resistant. ESBL producers have shown much higher rates of resistance than those non-ESBL to ciprofloxacin (ESBL versus non-ESBL, 74% versus 30%, *P* \< 0.01), gentamicin (69.5% versus 28.5%, *P* \< 0.01), co-trimoxazole (75.8% versus 36%, *P* \< 0.01), aztreonam (79% versus 20.5%, *P* \< 0.01), and levofloxacin (63% versus 40%, *P* \< 0.01). The great majority of Isolates were susceptible to Minocycline (ESBL versus non-ESBL, 82% versus 92.1%). All Isolates were susceptible to amikacin and imipenem (χ^2^ test for all groups).

Characteristics of the ESBL-producing Isolates
----------------------------------------------

All 197 Isolates with an ESBL phenotype tested positive for blaCTX-M and blaTEM using the consensus primers. We found 172 (87.3%) Isolates were positive for blaCTX-M, while 142(72.1%) Isolates were positive for blaTEM and 11 non-TEM-CTX-M-type Producers. In addition, most Isolates appeared to produce both TEM and CTX-M enzymes (128). Using nucleotide sequence analysis we found that the TEM enzymes detected two types which were TEM-1(138) and TEM-135(4) β-lactamase. Unlike the TEM enzymes, the CTX-M enzymes with a variety of types included CTX-M-3(16), CTX-M-14(77), CTX-M-15(64), CTX-M-55(9), CTX-M-64(1), CTX-M-65(2) and CTX-M-98(3) and the genes of CTX-M-14 and CTX-M-15 were in the majority.

Discussion
==========

In the article, 289 *E. coli* Isolates were collected from patients from July 2013 to August 2014; the detection rate of ESBL producers was 68.2% which was significantly higher than previous researches ([@B29]). Therefore, we should pay more attention to the problem and try to take appropriate prevention and remedial measures. We found that much more ESBL-producing Isolates in urinary surgery ward and ICU and the detection rate were higher than the other wards. Because a majority of patients in ICU acquired serious diseases lowering their immunity, and involved heavy use of antibiotics for a long time, both of which contributing to higher detection rates. And for patients in urinary surgery, higher detection rates were related to their selves characteristics, one of which was mainly urinary tract obstruction in favors of bacteria propagation, in addition to urethral catheterization, further increasing opportunities for infection. Besides, we found most ESBL-producing strains occur in old man or woman, because the elderly themselves have low immunity. And in the patients, one patient over 60 repeatedly infected with the ESBL-producing *E. coli*. As a long duration of extended-spectrum β-lactamase-producing *Enterobacteriaceae* carriage after discharge ([@B5]), we concluded that those patients underlying chronic illnesses which had lowered their immunity were apt to be infected with ESBL-producing *E. coli*. Therefore, we should initiate active interventions and treatments.

The susceptibility test data showed that the ESBL producers which were resistant to most-lactams and frequently resistant to the non-β-lactam antibiotics, for example, fluoroquinolones and aminoglycosides. If patients are infected by ESBL producers, cefmetazole, or imipenem will be chosen before results of antibiotic susceptibility test having been done. But if patients are in a critical condition, we should make choice of carbapenems ([@B22]). ESBL producers have shown much higher rates of resistance than those non-ESBL. Therefore, we should avoid antibiotics abuse in outpatient clinic and community hospitals, reducing opportunities for emergence of ESBLs.

TEM is the main type of β-lactamase, the TEM-1 group being the most common ones. CTX-M enzymes was a new group of plasmid-mediated ESBLs which has become the predominant ESBLs reported in Europe from last decade and has increased dramatically in many countries ([@B6]; [@B8]; [@B19]; [@B24]). In different geographic areas, the antibiotic consumption and dissimilar risk factors might have also contributed to the current epidemiology of CTX-M enzymes. Our study found that the CTX-M-14 and CTX-M-15 were in the majority, [@B12] and [@B15] coincided with that.

Even though we have explored ESBLs epidemiology, resistance and resistant genotypes in three hospitals of Shandong province, with limitation of small samples, we cannot provide enough theoretical and practical guidance for clinical treatment. In the future research, we should base upon more large survey samples from perspective of increasing patients, hospitals and regions. On the other hand, because of much more ESBL producers resistant to carbapenems, to conduct a targeted research, we will focus on carbapenem-resistant *Enterobacteriaceae* ([@B10]; [@B1]). Given carbapenems being the first-line agent for patients with ESBL-producing bacteria, the occurrence of resistant organisms could be related to carbapenems, and then we will explore whether non-carbapenems plays more efficient role in infections with ESBL-producing *Enterobacteriaceae*.

Generally speaking, much more ESBL producers are detected among *E. coli* in China. The drug resistance rate of *E. coli* is high, with the tendency getting higher. Attaching more importance to monitor the drug resistance of bacterium and reasonable application and control abuse of antibiotics in clinic. Based on local database, our research have clarified the clinical and epidemiological features in Shandong province, which contributes to provide guidance for identifying appropriate treatment plans according to patients characteristics, especially for patients underlying chronic illnesses. We should take measures appropriately, and then contributing to avoiding delay the conditions of patients and medical resources waste.
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